About Us

Therapeutic Systems Research Laboratories (TSRL), Inc. is a privately owned preclinical accelerator based in Ann Arbor, Michigan. Our 7,200 sq. ft. facility has 5,000 sq. ft. of wet lab space, and includes: analytical chemistry, formulation, cell culture, and in vivo testing. We employ nine full-time employees and generate revenue from royalties and grants.

About Us ›

Our Approach

We build on our success co-developing technologies through academic partnerships by providing infrastructure, expertise, and an avenue to non-dilutive funding. In an effort to advance our lead candidates into clinical development, we have developed an asset-centric portfolio built on promising lead-stage anti-infective compounds.

Our Approach ›

Spotlight

DNA Antivirals (.pdf)

Bridging the Gap

Questions? Contact Us ›

 
 

Recent News

Featured
Picture1.png
TSRL, Inc. Awarded $3 Million NIH Grant to Develop a First-in-Class Oral Antibiotic
Read More →
TSRL, Inc. awarded NIH Grant to Discover Novel, Safe, Efficacious Heparin Reversal Therapy
TSRL, Inc. awarded NIH Grant to Discover Novel, Safe, Efficacious Heparin Reversal Therapy
Read More →
TSRL, Inc.’s Microarray Patch (MAP) of Trospium Chloride for Overactive Bladder Disease Continues Development with Grant from the NIH
TSRL, Inc.’s Microarray Patch (MAP) of Trospium Chloride for Overactive Bladder Disease Continues Development with Grant from the NIH

TSRL, Inc., a privately-held preclinical accelerator, has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institute of Health (NIH) for about $300,000 over 12 months.

TSRL, Inc. will continue to broaden its MAP portfolio with the development of a once-a-week patch of Trospium Chloride (TC) optimized for improved tolerance and patient outcomes in overactive bladder (OB) disease.

Read More →
TSRL, Inc. Awarded $1.7 NIH Grant to Develop Synthetic High-Density Lipoproteins (sHDL) for Treatment of Infection Complications such as Sepsis
TSRL, Inc. Awarded $1.7 NIH Grant to Develop Synthetic High-Density Lipoproteins (sHDL) for Treatment of Infection Complications such as Sepsis

Ann Arbor, Michigan, September 5, 2021 – TSRL, Inc., announces its plans to develop a sHDL lead candidate for treatment of infection complications such as sepsis in collaboration with Anna Schwendeman, PhD, from University of Michigan. The company was awarded a Direct-to-Phase II Small Business Innovation Research (SBIR) grant from the National Institute of General Medical Sciences (NIGMS) of the National Institute of Health (NIH). TSRL and its collaborator, Dr. Anna Schwendeman, will receive an estimated $1.7M over the next two years to advance SPS-701 through preclinical development towards GLP toxicology testing.

Read More →